Related Experiment Video
Updated: Feb 8, 2026

Isolating Malignant and Non-Malignant B Cells from lck:eGFP Zebrafish
Published on: February 22, 2019
Toxicities associated with immunotherapies for hematologic malignancies
Mark B Leick1, Marcela V Maus1
1Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA, USA.
Abstract:
Immunotherapy has generated tremendous hope for patients with cancer that is refractory to standard approaches. Hematologic malignancies have taken the lead in harnessing the most recent advances in cell-based immunotherapies, such as CAR T cells, and some patients have achieved durable remissions. However, these T-cell-engaging therapies are associated with a new set of toxicities which need to be managed by caretakers, oncologists, nurses, and healthcare staff. In this review we provide an overview of the toxicity of some of these revolutionary agents including bispecific T cell engagers, checkpoint inhibitors, chimeric antigen receptor T-cells.
Related Concept Videos
Tumor Immunotherapy
Toxic Reactions: Overview
Toxicity falls into two primary categories: local and systemic.
Local toxicity appears at the exposure site, such as protein denaturation caused by caustic substances.
In contrast, systemic toxicity requires the toxic agent's absorption and distribution,...
Frequency-dependent Selection
Predator-Prey Interactions
Responses to Salt Stress
Comparative Excretory Systems

